KERI KENDALL: Open Payments
NPI 1376585364 · BEATRICE, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$675 in 38 payments from 14 companies in 2025. Trend: 2023 $117 · 2024 $392 · 2025 $675
Food & beverage: $675
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $213 |
| Novo Nordisk Inc | 7 | $111 |
| Novartis Pharmaceuticals Corporation | 6 | $109 |
| PFIZER INC. | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $31 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| Organon LLC | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
Products named: LEQVIO, UBRELVY, VRAYLAR, Wegovy, REXULTI, QULIPTA, Ozempic, Veozah.
Industry payments across NE — which companies pay providers there.
